Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years
Authors
Keywords
-
Journal
VACCINE
Volume 40, Issue 31, Pages 4190-4198
Publisher
Elsevier BV
Online
2022-06-10
DOI
10.1016/j.vaccine.2022.05.079
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
- (2021) Giuliana S. Oliveira et al. Vaccines
- A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults
- (2020) Cheryl A. Keech et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes
- (2020) Katrina M Nolan et al. Bioanalysis
- Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization
- (2019) Joanne M. O’Hara et al. Mucosal Immunology
- Screening for Th17-dependent pneumococcal vaccine antigens: comparison of murine and human cellular immune responses
- (2018) Ying-Jie Lu et al. INFECTION AND IMMUNITY
- Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides
- (2018) Danka Pavliakova et al. mSphere
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
- (2018) James T. Peterson et al. Human Vaccines & Immunotherapeutics
- Characteristics of serogroup 20 S.pneumoniae isolates from Brazil
- (2016) Juliana Caierão et al. BMC INFECTIOUS DISEASES
- Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection
- (2016) Y Wang et al. Mucosal Immunology
- Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults
- (2014) Christine Juergens et al. Human Vaccines & Immunotherapeutics
- Pneumococcal infection in adults: burden of disease
- (2013) J.J.C. Drijkoningen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity
- (2013) F. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of a Fourfold Multiplexed Opsonophagocytosis Assay for Pneumococcal Antibodies against Additional Serotypes and Discovery of Serological Subtypes in Streptococcus pneumoniae Serotype 20
- (2012) Robert L. Burton et al. Clinical and Vaccine Immunology
- Pneumococcal Conjugate Vaccine for Adults: A New Paradigm
- (2012) P. R. Paradiso CLINICAL INFECTIOUS DISEASES
- Understanding the burden of pneumococcal disease in adults
- (2012) F. Blasi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Biochemical, Genetic, and Serological Characterization of Two Capsule Subtypes amongStreptococcus pneumoniaeSerotype 20 Strains
- (2012) Juan J. Calix et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TH17-Based Vaccine Design for Prevention of Streptococcus pneumoniae Colonization
- (2011) Kristin L. Moffitt et al. Cell Host & Microbe
- Serotype replacement in disease after pneumococcal vaccination
- (2011) Daniel M Weinberger et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More